- 112.9k views
HRD Evaluation in 4 types of Cancers
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.
About the Speaker
Dr. Shibichakravarthy Kannan
Precision Oncology, Founder & CEO in Oncophenomics Inc., Hyderabad
Upcoming Case Discussions
Technology Integration with Healthcare
Technology integration in healthcare is transforming the way medical services are delivered, enhancing efficiency and patient outcomes. Innovations such as telemedicine, electronic health records (EHR), and wearable devices allow for real-time monitoring and improved accessibility. Artificial intelligence (AI) and machine learning aid in early diagnosis and personalized treatment plans. Robotic surgeries and advanced imaging techniques offer precision and reduced recovery times. By combining technology with healthcare, providers can streamline operations, improve patient engagement, and deliver cost-effective care solutions.
Pediatric Obesity: Treatment Management
Treatment management for pediatric obesity combines lifestyle changes, family support, and, in severe cases, medical interventions. Family-based strategies are key, encouraging healthy eating habits, regular physical activity, and reduced screen time. Behavioral therapy helps set achievable goals and address barriers, empowering children and families to make sustainable lifestyle adjustments. Dietitians often assist in designing individualized meal plans that focus on nutrient-rich foods and limit calorie-dense options. In cases of severe obesity with related health conditions, medications or surgery may be considered, particularly for adolescents. Continuous monitoring and support from healthcare providers are essential for long-term success and health improvement.
Clinician’s Approach to Sleep Apnea
A clinician's approach to sleep apnea begins with a thorough assessment of the patient's medical history, symptoms (such as snoring, choking, and daytime fatigue), and risk factors like obesity or hypertension. Diagnosis is typically confirmed through polysomnography or home sleep apnea testing, followed by treatment strategies such as continuous positive airway pressure (CPAP), lifestyle modifications, or surgical interventions depending on the severity and type of sleep apnea.
Case Based Approach to Arthritis
A case-based approach to arthritis involves analyzing individual patient cases to tailor diagnostic and therapeutic strategies based on specific symptoms, disease progression, and underlying causes. This method enhances clinical decision-making by providing personalized treatment plans and improving patient outcomes in conditions like osteoarthritis, rheumatoid arthritis, and psoriatic arthritis.
Falls and Fractures in Older Adults: Prevention and Immediate Care
Falls and fractures in older adults are common and can lead to significant morbidity, highlighting the importance of fall prevention strategies such as strength training, balance exercises, and home safety modifications. Immediate care involves quick assessment for fractures, pain management, and stabilization, along with appropriate transport to healthcare facilities for further evaluation and treatment.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Shibichakravarthy Kannan 's Talks on Assimilate
- 18th-July-2023, TIME : 5:00PM - 6:00PM
- 0
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.
- 18th-July-2023, TIME : 5:00PM - 6:00PM
- 0
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.
- 18th-July-2023, TIME : 5:00PM - 6:00PM
- 0
HRD (Homologous Recombination Deficiency) evaluation plays a crucial role in assessing the genetic characteristics and treatment strategies for various types of cancers. In breast cancer, it helps identify patients with DNA repair defects that may benefit from targeted therapies. In ovarian cancer aids in determining the potential responsiveness to PARP inhibitors, a class of drugs used in DNA repair-deficient tumors. In prostate cancer, it assists in identifying patients who may respond well to certain DNA-damaging agents or PARP inhibitors. Understanding HRD status in pancreatic cancer helps in identifying patients with defects in DNA repair pathways, which may influence treatment decisions. In lung cancer allows for the identification of patients who may benefit from DNA damage response-targeted therapies.